The Novel Targets in the Ovarian Cancer Treatment Paradigm publication covers some of the latest practice-changing advances as it relates to novel targets in the treatment for patients with advanced ovarian cancer.
UpRi Looks to Add Superior Treatment Option in Platinum-Resistant Ovarian Cancer
Investigators are hoping to dramatically improve the platinum-resistant ovarian cancer treatment paradigm with the development of the first-in-class antibody-drug conjugate upifitamab rilsodotin.
Dr. Birrer on Remaining Questions in Platinum-Sensitive Ovarian Cancer
Michael J. Birrer, MD, PhD, discussed remaining questions when addressing platinum-sensitive ovarian cancer.
Evolving Technology Behind ADCs Could Improve Benefit in Advanced Ovarian Cancer
Michael Birrer, MD, PhD, discusses how new technology has transformed ADCs, how upifitamab rilsodotin could have a role in treating patients with ovarian cancer, and why the NaPi2B biomarker could be a vital target.
Upifitamab Rilsodotin Under Investigation in Several Trials to Bridge Unmet Need in Recurrent Ovarian Cancer
Debra L. Richardson, MD, FACS, FACOG, discusses the role of NaPi2b as a target for upifitamab rilsodotin, data that have emerged from the ongoing phase 1/2 UPLIFT trial, and the development of other studies like UPNEXT and UPGRADE that are further evaluating upifitamab rilsodotin in patients with ovarian cancer.
Dr. Richardson on the Rationale for the UPNEXT Trial in Ovarian Cancer
Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.
Upifitamab Rilsodotin Has Potential to Address Unmet Need in Recurrent Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses the unmet needs for patients with ovarian cancer and the clinical trials that seeking to address those needs, including the ADC upifitamab rilsodotin.
Dr. Monk on the Emergence of NaPi2b as a Target in Ovarian Cancer
Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.
Dr. Monk on Remaining Unmet Needs in Recurrent Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses existing unmet needs in the treatment of patients with recurrent ovarian cancer.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.